Powder: -20°C for 3 years | In solvent: -80°C for 1 year
CTX-2026, a fully human antibody, targets and binds to CD277, demonstrating an anti-tumor effect in ovarian tumor models, and is utilized in cancer research [1].
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | Inquiry | Inquiry | |
5 mg | Inquiry | Inquiry |
Description | CTX-2026, a fully human antibody, targets and binds to CD277, demonstrating an anti-tumor effect in ovarian tumor models, and is utilized in cancer research [1]. |
In vitro | CTX-2026 (1 μg/mL; 12 h) enhances the targeted killing capacity of Vγ9Vδ2 T cells from various individuals against BTN3A1-expressing OVCAR3 cells and primary high-grade serous ovarian cancer (HGSOC) cells [1]. |
In vivo | CTX-2026 administered intraperitoneally at a dosage of 5 mg/kg every three days for a duration of 15 days influenced the progression of tumor growth in mice bearing NY-OVCAR3 tumors [1]. |
Molecular Weight | N/A |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.